The useful markers are WT1 (specificity 100%, sensitivity 76%), CA125 (specificity 85%, sensitivity 90%) for ovarian primaries, and GCDFP (specificity 100%, sensitivity 43%) for metastatic breast carcinoma1.
|
Primary ovarian carcinoma |
Primary breast carcinoma |
Breast carcinoma metastatic to ovary |
p |
|||
other |
|||||||
31/33 (4+: 24, 3+: 3, 2+: 2, 1+: 2, neg: 2)1 |
1/9 (0/5 clear cell, 0/2 mucinous, 1/2 endometrioid)1 |
0/361 |
0/391 |
<0.0011 |
|||
32/33 (4+: 18, 3+: 6, 2+: 3, 1+: 5, neg: 1)1 |
6/9 (4/5 clear cell, 1/2 mucinous, 1/2 endometrioid)1 |
6/36 (ductal/mixed: 4+: 0, 3+: 0, 2+: 1, 1+: 3, neg: 21, lobular: 1+: 2, neg: 9)1 |
5/39 (ductal/mixed: 3+: 1, 1+: 1, neg; 18, lobular: 2+: 1, 1+: 2, neg: 16)1 |
<0.0011 |
|||
0/331 |
0/9 (0/5 clear cell, 0/2 mucinous, 0/2 endometrioid)1 |
5/36 (ductal/mixed: 4+: 1, 1+: 3, neg: 21, lobular: 1+: 1, neg: 10)1 |
17/39 (ductal/mixed: 2+: 3, 1+: 5, neg: 12, lobular: 3+: 2, 1+: 7, neg: 10)1 |
<0.0011 |
|||
7/33 (4+: 0, 3+: 0, 2+: 4, 1+: 3, neg: 26)1 |
2/9 (1/5 clear cell, 1/2 mucinous, 0/2 endometrioid)1 |
8/36 (ductal/mixed: 4+: 1, 1+: 7, neg: 17, lobular: neg: 11)1 |
13/39 (ductal/mixed: 2+: 2, 1+: 6, neg: 12, lobular: 2+: 2, 1+: 3, neg: 14)1 |
NS1 |
|||
33/33 (4+: 31, 3+: 2)1 |
9/9 (5/5 clear cell, 2/2 mucinous, 2/2 endometrioid)1 |
36/36 (ductal/mixed: 4+: 22, 3+: 2, 2+: 1, lobular: 4+: 10, 2+: 1)1 |
37/39 (ductal/mixed: 4+: 14, 3+: 2, 2+: 1, 1+: 1, neg: 2, lobular: 4+: 19)1 |
NS1 |
|||
6/33 (4+: 0, 3+: 0, 2+: 1, 1+: 5, neg: 26)1 |
4/9 (2/5 clear cell, 1/2 mucinous, 1/2 endometrioid)1 |
3/36 (ductal/mixed: 2+: 1, 1+: 3, neg; 22, lobular: neg: 11. minor error in paper)1 |
12/39 (ductal/mixed: 2+: 1, 1+: 2, neg: 17, lobular: 1+: 9, neg: 10)1 |
0.051 |
|||
Primary ovarian carcinoma requires debulking and chemotherapy. Metastatic breast carcinoma does not require debulking and requires a different chemotherapeutic regimen.
The five-year survival of primary ovarian carcinoma varies from 5% to 90%, depending on stage and resectability, compared with less than 10% five-year survival for patients with breast carcinoma metastatic to the ovary.
This page last revised 21.1.2006.
©SMUHT/PW Bishop